Fondaparinux versus enoxaparin in acute coronary syndromes [1]

New England Journal of Medicine

Volumn 354, Issue 26, 2006, Pages 2829-

  Majure, David T ^a   Aberegg, Scott K ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CORONARY ARTERY BYPASS GRAFT; HUMAN; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; ENOXAPARIN; HEMORRHAGE; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; POLYSACCHARIDES; RESEARCH DESIGN;

EID: 33745638754     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061206     Document Type: Letter

References (3)

1. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76.
2. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
3. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006;354:1667-9.